A Case of Philadelphia Chromosome-Positive Acute Myeloid Leukemia (Ph+AML) of Primary Drug Resistance and Relevant Literature Review
Abstract: 费城染色体阳性急性髓系白血病(Ph+AML)是一种罕见的AML亚型，2016年修订的世界卫生组织(WTO)髓系恶性肿瘤将其归类为预后不良伴有遗传学异常的AML暂定型。Ph+AML是有别于慢性髓系白血病的一组高度复杂的异质性疾病，对化疗反应差，易复发，预后不佳，具有独特的临床和血液学特点。 Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML), as a rare subtype of AML, is classified as provisional AML of poor prognosis accompanied with genetic abnormalities according to the 2016 revision of World Health Organization (WTO)-defined myeloid malignancy. Ph+AML is a group of highly complex heterogeneous diseases different from chronic myeloid leukemia (CML) with poor response to chemotherapy. It is characterized by easy recurrence, poor prognosis, and unique clinical and hematological features.
Click here to see the statistics on "World Journal of Cancer Research" .